BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds ...
Framing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has been under pressure recently, with the ...
Bio-Rad stock looks undervalued, boosted by its Sartorius stake, but headwinds and volatile guidance cap upside. Click here ...
Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...
Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...
While analyzing Bio-Rad Laboratories’ (BIO) most recent 10-K, my firm’s analysts noticed that its non-operating income not only overstates GAAP net income but could negatively impact the firm’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results